Skip to main content
PMC home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2004 Mar;50:425–433.

Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.

Stewart B Harris 1, Cynthia N Lank 1
PMCID: PMC2214567  PMID: 15318682

Full Text

The Full Text of this article is available as a PDF (207.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakris G. L., Copley J. B., Vicknair N., Sadler R., Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov;50(5):1641–1650. doi: 10.1038/ki.1996.480. [DOI] [PubMed] [Google Scholar]
  2. Chiasson Jean-Louis, Josse Robert G., Gomis Ramon, Hanefeld Markolf, Karasik Avraham, Laakso Markku, STOP-NIDDM Trail Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):2072–2077. doi: 10.1016/S0140-6736(02)08905-5. [DOI] [PubMed] [Google Scholar]
  3. Coutinho M., Gerstein H. C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 Feb;22(2):233–240. doi: 10.2337/diacare.22.2.233. [DOI] [PubMed] [Google Scholar]
  4. Dawson Keith G., Gomes Daniel, Gerstein Hertzel, Blanchard James F., Kahler Kristijan H. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002 Aug;25(8):1303–1307. doi: 10.2337/diacare.25.8.1303. [DOI] [PubMed] [Google Scholar]
  5. Gaede Peter, Vedel Pernille, Larsen Nicolai, Jensen Gunnar V. H., Parving Hans-Henrik, Pedersen Oluf. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383–393. doi: 10.1056/NEJMoa021778. [DOI] [PubMed] [Google Scholar]
  6. Genest Jacques, Frohlich Jiri, Fodor George, McPherson Ruth, Working Group on Hypercholesterolemia and Other Dyslipidemias Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003 Oct 28;169(9):921–924. [PMC free article] [PubMed] [Google Scholar]
  7. Harris Stewart B., Stewart Moira, Brown Judith Belle, Wetmore Stephen, Faulds Catherine, Webster-Bogaert Susan, Porter Sheila. Type 2 diabetes in family practice. Room for improvement. Can Fam Physician. 2003 Jun;49:778–785. [PMC free article] [PubMed] [Google Scholar]
  8. Knowler William C., Barrett-Connor Elizabeth, Fowler Sarah E., Hamman Richard F., Lachin John M., Walker Elizabeth A., Nathan David M., Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393–403. doi: 10.1056/NEJMoa012512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leiter L. A., Barr A., Bélanger A., Lubin S., Ross S. A., Tildesley H. D., Fontaine N., Diabetes Screening in Canada (DIASCAN) Study Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care. 2001 Jun;24(6):1038–1043. doi: 10.2337/diacare.24.6.1038. [DOI] [PubMed] [Google Scholar]
  10. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  11. Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851–860. doi: 10.1056/NEJMoa011303. [DOI] [PubMed] [Google Scholar]
  12. McAlister Finlay A., Zarnke Kelly B., Campbell Norman R. C., Feldman Ross D., Levine Mitchell, Mahon Jeff, Grover Steven A., Lewanczuk Richard, Leenen Frans, Tobe Sheldon. The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol. 2002 Jun;18(6):625–641. [PubMed] [Google Scholar]
  13. Mokdad A. H., Bowman B. A., Ford E. S., Vinicor F., Marks J. S., Koplan J. P. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001 Sep 12;286(10):1195–1200. doi: 10.1001/jama.286.10.1195. [DOI] [PubMed] [Google Scholar]
  14. Narayan K. M., Thompson T. J., Boyle J. P., Beckles G. L., Engelgau M. M., Vinicor F., Williamson D. F. The use of population attributable risk to estimate the impact of prevention and early detection of type 2 diabetes on population-wide mortality risk in US males. Health Care Manag Sci. 1999 Dec;2(4):223–227. doi: 10.1023/a:1019048114376. [DOI] [PubMed] [Google Scholar]
  15. Parving H. H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–878. doi: 10.1056/NEJMoa011489. [DOI] [PubMed] [Google Scholar]
  16. Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993 Apr 15;118(8):577–581. doi: 10.7326/0003-4819-118-8-199304150-00001. [DOI] [PubMed] [Google Scholar]
  17. Saydah Sharon H., Byrd-Holt Danita, Harris Maureen I. Projected impact of implementing the results of the diabetes prevention program in the U.S. population. Diabetes Care. 2002 Nov;25(11):1940–1945. doi: 10.2337/diacare.25.11.1940. [DOI] [PubMed] [Google Scholar]
  18. Stratton I. M., Adler A. I., Neil H. A., Matthews D. R., Manley S. E., Cull C. A., Hadden D., Turner R. C., Holman R. R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405–412. doi: 10.1136/bmj.321.7258.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tremblay M. S., Willms J. D. Secular trends in the body mass index of Canadian children. CMAJ. 2000 Nov 28;163(11):1429–1433. [PMC free article] [PubMed] [Google Scholar]
  20. Tuomilehto J., Lindström J., Eriksson J. G., Valle T. T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343–1350. doi: 10.1056/NEJM200105033441801. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES